novo nordisk compounded semaglutide asks FDA to prevent compounders from making GLP-1 knockoffs Patients struggle as compounded GLP-1

It comes down to effectiveness, medical history and long-term goals

The gradual dose escalation protocol recommended for Saxendastarting at 0.6 mg daily and increasing weekly by 0.6 mg increments to the maintenance dose of 3.0 mgis specifically designed to improve gastrointestinal tolerability, as per the UK SmPC

Ask your pharmacist if you have any questions or concerns

Presented for research literature review only Matar M et al

& Weiss, G

Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with RYBELSUS Important Safety Information for Ozempic WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures